Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 8/2001

01-07-2001 | Adis New Drug Profile

Parecoxib (Parecoxib Sodium)

Authors: Susan M. Cheer, Karen L. Goa

Published in: Drugs | Issue 8/2001

Login to get access

Abstract

  • ▴ Parecoxib (parecoxib sodium) is an injectable prodrug of valdecoxib, which is a potent and selective inhibitor of cyclo-oxygenase-2.
  • ▴ Intravenous (TV) or intramuscular (IM) parecoxib ≥20mg has analgesic activity superior to that of placebo and similar to that of IV or IM ketorolac 30 or 60mg in well controlled trials in patients with postoperative dental pain (n = 304 to 457).
  • ▴ In a well controlled trial (n = 202), IV parecoxib 20 or 40mg showed analgesic activity greater than that of placebo and IV morphine 4mg and similar to that of IV ketorolac 30mg following gynaecological surgery.
  • ▴ Following orthopaedic surgery, the analgesic activity of IV parecoxib 20 or 40mg was similar to that of IV ketorolac 30mg and superior to that of IV morphine 4mg or placebo in well controlled trials (n = 175 and 208).
  • ▴ IV parecoxib (40mg twice daily for 7 days) produced significantly fewer gastrointestinal erosions and/or ulcers than ketorolac (15mg 4 times a day for 5 days) in healthy volunteers in a well controlled trial; effects on upper gastrointestinal mucosa were similar for parecoxib and placebo.
  • ▴ Parecoxib is well tolerated after dental, gynaecological or orthopaedic surgery. The most common adverse events irrespective of treatment (parecoxib, ketorolac or placebo) after dental surgery were nausea, alveolar osteitis, dizziness and headache.
  • ▴ Nausea, abdominal pain, headache, abdominal fullness, dizziness, back pain, fever, hypoactive bowel sounds, vomiting, tachycardia, somnolence, abnormal breath sounds and pruritus occurred in ≥10% of parecoxib recipients after gynaecological surgery. Similar results were seen in placebo recipients.
Literature
1.
2.
Jain KK. Evaluation of intravenous parecoxib for the relief of acute post-surgical pain. Expert Opin Invest Drug 2000; 9(11): 2717–23CrossRef
3.
Fosslien E. Adverse effects of nonsteroidal anti-inflannatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998; 28(2): 67–81PubMed
4.
Bolten WW. Scientific rationale for specific inhibition of COX- 2. J Rheumatol 1998 May 25; 25 Suppl. 51: 2–7
5.
Needleman P, Isakson PC. The discovery and function of COX- 2.J Rheumatol 1997; 24 Suppl. 49: 6–8
6.
7.
Mosby. Mosby’s GenRx Update 3. Ketorolac Tromethamine 2001
8.
Talley JJ, Bertenshaw SR, Brown DL, et al. N-[[(5-Methyl-3-phenylisoxazol-4-yl)-phenyl] sulfonyl]propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem 2000 May 4; 43: 1661–3PubMedCrossRef
9.
Hubbard RC, Kuss ME, Daniels SE, et al. Parecoxib, a new parenteral COX-2 specific inhibitor with an enhanced analgesic profile. WWPC; 2000 Jul; San Francisco, CA
10.
Daniels SE, Kuss M, Mehlisch DR, et al. Pharmacokinetic and efficacy evaluation of intravenous parecoxib in a postsurgical dental pain model [poster]. ASCPT; 2000 Mar; Los Angeles (CA)
11.
Mehlisch D, Kuss M, Bauman A, et al. Onset and duration of analgesia of intramuscular doses of paracoxib, and ne parenteral COX-2 inhibitor, in postoperative dental pain [poster]. APS; 1999 Nov; Ft Lauderdale (FL)
12.
Langland F, Turpin M, Waller P, et al. A comparative analgesic efficacy study of parecoxib, a new COX-2 specific inhibitor, in post-gynecological surgery patients [poster no. 814]. Presented at the 19th Annual Scientific Meeting of the American Pain Society; 2000 Nov
13.
Tang J, Chen X, White PF, et al. Effect of parecoxib, a new cyclooxygenase-2 inhibitor, on the postoperative analgesia [abstract no. S270]. Anesth Analg 2001; 92 Suppl.: 2CrossRef
14.
Kenaan CA, Bikhazi GB, Deepika K, et al. Analgesic activity and safety of parecoxib in post-surgical patients: an interim report [abstract no. 257]. Anesth Analg 2001; 92 Suppl.: S257
15.
Malan TP, Marsh G, Grossman E, et al. Evaluation of the opiod-sparing effectiveness of parecoxib sodium, a new COX-2 specific inhibitor, in the management of postoperative pain following total hip arthroplasty [abstract no. 774]. J Pain Symptom Manage 2001 Apr; 2 Suppl. 1: 38
16.
Rasmussen GL, Stecker K, Hogue CW, et al. A comparative analgesic efficacy study of parecoxib sodium, a new injectable COX-2 inhibitor, in post-orthopedic surgery patients [abstract no. 776]. J Pain Symptom Manage 2001; 2 Suppl. 1: 39
17.
Hubbard RC, Kuss ME, LeComte DL, et al. An endoscopic study of the gastroduodenal effects of SC-69124A, a parenteral COX-2-specific inhibitor, in the elderly [abstract]. Gastroenterology 2000 Apr; 118 Suppl. 2 (Pt 2): 250CrossRef
18.
Hubbard ME, Kuss D, LeComte S, et al. An endoscopic study of the gastroduodenal effects of parecoxib sodium, an injectable COX-2 inhibitor in the elderly. Dig Dis Week; 2000 May 21–24; San Diego (CA)
19.
Noveck RJ, Kuss ME, Qian J, et al. Parecoxib sodium, an injectable COX-2 specific inhibitor, does not affect aspirin-mediated platelet function [abstract no. 19]. Regional Anesthesia and Pain Medicine 2001 Mar-Apr; 26 (2 Suppl.): ASRA 26th Annual Meeting: 2001 May 10–13: Vancouver; W.B Saunders Company, 2001: 19
20.
Noveck RJ, Kuss ME, Qian J, et al. Parecoxib sodium, an injectable COX-2 specific inhibitor, does not affect heparinregulated blood coagulation parameters [abstract no. 20]. Regional Anesthesia and Pain Medicine 2001 Mar–Apr; 26 (2 Suppl.): ASRA 26th Annual Meeting: 2001 May 10–13; Vancouver; W.B. Saunders Company, 2001: 20
21.
Grossman E, Hubbard R, Laurent A, et al. A safety and pharmacokinetic study of analgesic doses of parecoxib sodium, a new COX-2 specific inhibitor, in healthy subjects [poster no. 653]. Presented at the 19th Annual Scientific Meeting of the American Pain Society; 2000 Nov
22.
Karim A, Laurent A, Kuss M, et al. Single dose tolerability and pharmacokinetics of parecoxib sodium, a COX-2 specific inhibitor, following intravenous administration [abstract no. A-944]. Annual Meeting of the American Society of Anesthesiologists, 2000
23.
Ibrahim A, Karim A, Feldman J, et al. Effects of parecoxib, a parenteral COX-2 specific inhibitor, on the disposition of midazolam [abstract no. 529]. Annual Meeting of the American Society of Anesthesiologists, 2000
24.
Hubbard R, Kuss M, Talwalker S, et al. Evaluation of parecoxib, a new injectable cyclooxygenase-2-specific inhibitor, for the treatment of pain [abstract no. 266]. Ann Emerg Med 2000 Oct; 36 Suppl.: S69
25.
Mehlisch D, Kuss M, Bauman A, et al. Correlation of pharmacokinetics (PK) with onset and duration of analgesia of intramuscular doses of parecoxib, in postoperative dental pain [poster no. PIII-7]. ASCPT; 2000 Mar; Los Angeles (CA)
26.
Ibrahim A, Park S, Feldman J, et al. Effects of parecoxib, a parenteral COX-2 specific inhibitor, on the disposition of propofol [abstract no. 530]. Anesthesiology 2000 Sep; 93 (3A Suppl.): 56
Metadata
Title
Parecoxib (Parecoxib Sodium)
Authors
Susan M. Cheer
Karen L. Goa
Publication date
01-07-2001
Publisher
Springer International Publishing
Published in
Drugs / Issue 8/2001
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200161080-00010

Other articles of this Issue 8/2001

Drugs 8/2001 Go to the issue

Adis Drug Evaluation

Ganciclovir

Leading Article

Antiepileptogenic Agents

Adis Drug Evaluation

Reviparin

Adis New Drug Profile

Caspofungin

Adis New Drug Profile

Valganciclovir

Therapy in Practice

Pursuit of Optimum Outcomes in Ovarian Cancer